TY - JOUR AU - Stringer-Reasor, Erica M. AU - May, Jori E. AU - Olariu, Eva AU - Caterinicchia, Valerie AU - Li, Yufeng AU - Chen, Dongquan AU - Della Manna, Deborah L. AU - Rocque, Gabrielle B. AU - Vaklavas, Christos AU - Falkson, Carla I. AU - Nabell, Lisle M. AU - Acosta, Edward P. AU - Forero-Torres, Andres AU - Yang, Eddy S. PY - 2021 DA - 2021/03/04 TI - An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer JO - Breast Cancer Research SP - 30 VL - 23 IS - 1 AB - Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple-negative breast cancer (TNBC) with intact DNA repair, we have previously shown an induced synthetic lethality with combined EGFR inhibition and PARPi. Here, we report the safety and clinical activity of lapatinib and veliparib in patients with metastatic TNBC. SN - 1465-542X UR - https://doi.org/10.1186/s13058-021-01408-9 DO - 10.1186/s13058-021-01408-9 ID - Stringer-Reasor2021 ER -